Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 110.55M P/E - EPS this Y 25.80% Ern Qtrly Grth -
Income -47.97M Forward P/E -2.52 EPS next Y 34.80% 50D Avg Chg -17.00%
Sales 82.51M PEG - EPS past 5Y - 200D Avg Chg -54.00%
Dividend N/A Price/Book 2.46 EPS next 5Y - 52W High Chg -88.00%
Recommedations 2.20 Quick Ratio 3.19 Shares Outstanding 52.20M 52W Low Chg 1.00%
Insider Own 11.68% ROA -15.96% Shares Float 43.59M Beta 1.70
Inst Own 30.57% ROE -92.13% Shares Shorted/Prior 2.76M/2.91M Price 2.14
Gross Margin 91.28% Profit Margin -58.13% Avg. Volume 968,046 Target Price 8.50
Oper. Margin -60.04% Earnings Date May 1 Volume 5,674,527 Change -2.28%
About G1 Therapeutics, Inc.

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

G1 Therapeutics, Inc. News
04/19/24 G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Shift From Loss To Profit
04/17/24 G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
04/04/24 G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
04/01/24 G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/29/24 G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript
02/28/24 Q4 2023 G1 Therapeutics Inc Earnings Call
02/28/24 G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates
02/28/24 G1 Therapeutics Inc (GTHX) Reports Strong Revenue Growth in 2023
02/28/24 G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
02/27/24 G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
02/17/24 G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 47% loss last week hit both individual investors who own 60% as well as institutions
02/15/24 G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024
02/12/24 G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
01/08/24 G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
01/03/24 Insider Sell: President and CEO Bailey John E. (Jack) Jr. Sells 32,983 Shares of G1 Therapeutics Inc
01/03/24 G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
12/13/23 Insider Sell Alert: Chief Medical Officer Rajesh Malik Offloads Shares of G1 Therapeutics Inc
12/08/23 G1 Therapeutics (NASDAQ:GTHX) adds US$67m to market cap in the past 7 days, though investors from five years ago are still down 90%
12/05/23 G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
11/29/23 G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium
GTHX Chatroom

User Image DulyNoted Posted - 1 hour ago

$GTHX Not much selling today.

User Image DueDiligence9601 Posted - 4 hours ago

$GTHX Some good lots going pre-market.

User Image TheBishop1 Posted - 19 hours ago

$GTHX I imagine if we can break the $5 mark…it’s running to $8…been saying that for awhile…..but it’s like spring at $5…then people will FOMO back in…hopefully before Q3 TNBC …settle at $8-$10…then explode from there with positive TNBC…that’s what I’m hoping…

User Image RonIsWrong Posted - 2 days ago

$GTHX my overly annotated chart, fwiw. ideally, it establishes support here (maybe down to 3.85) and then pushes higher.

User Image Pharmer23 Posted - 3 days ago

@Spartrap @Mnof $GTHX had the same issue with TNBC. They got slaughtered for the same reason . It has recovered quite a bit .

User Image Paultown1 Posted - 4 days ago

$GTHX Hi guys…still have some common and rooting for this company, but had to finish out closing my April 2.50s today, so my big bet on this name has now dwindled (I originally had over 7,000 of the April 2.50s and 3,000+ of the January $2.50s I bought back in August/September/October). May be interesting to know I’ve had to short about 500,000 GTHX shares over the last 2 weeks to unwind some of my call options (because the calls weren’t bidding intrinsic value). It was encouraging to see buyers take them, particularly last week when we stayed up in the 4.60 to 4.88 range when XBI was getting hammered (this stock has been resilient). So good luck to all! This has been a great trade, but more importantly, I hope more than anything we’ll hear news that GTHX is giving TNBC patients more precious time with their families.

User Image willthethrill2 Posted - 4 days ago

$GTHX jack is going to chicago in june!!!

User Image tepperoni Posted - 4 days ago

$GTHX trend

User Image DulyNoted Posted - 4 days ago

$GTHX Stop-loss orders is a good way to lose money.

User Image TheBishop1 Posted - 4 days ago

$GTHX My apologies peeps…bought 2k shares at $4.20…then nose dives to $4.08…SMH

User Image chance111 Posted - 5 days ago

$GTHX Over the past 2 months, biotech stocks have been in a steady decline after experiencing upward movement for more than 6 months. Hopefully, we are not going back to the previous decline in the xbi for more than a year. I don't even know the reason for the recent decline. Either way, this will have a negative impact regardless of news coming out on G1. If the trend continues, any gains will be less with good news then we all are expecting. If the news in not good, expect declines that will bring us down to those ridiculous lows we saw the end of last year. Just a warning for people to be cautious especially in light of world news. Israel WILL launch a major attack in the near future against Iran and it will devastate an already unsteady market.

User Image ScoobieDoo Posted - 5 days ago

$GTHX https://twitter.com/EDNewsChina/status/1780231470029869088

User Image Nota_Trustfund_Baby Posted - 5 days ago

$GTHX buying looks good compared to other bio charts where its sliding at close

User Image steven1x Posted - 5 days ago

$GTHX https://edge.media-server.com/mmc/p/jfdeqmbr/

User Image G101SPM Posted - 5 days ago

$GTHX $4.27 bid. DAC (dollar average cost) (4) $1.814 last $1.23 (10.17.23). EXIT $12,50 - Legacy Holding - LH. NEWS: G1 Therapeutics, Inc. will host a webcast and conference call to provide a financial and corporate update for the first quarter of 2024 on Wednesday May 1, 2024, at 8:30 a.m. ET.

User Image DueDiligence9601 Posted - 6 days ago

$GTHX I like the pre-market earnings calls.

User Image Stock_Titan Posted - 6 days ago

$GTHX G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024 https://www.stocktitan.net/news/GTHX/g1-therapeutics-to-release-first-quarter-2024-financial-results-and-pztmz0jddpge.html

User Image steven1x Posted - 6 days ago

$GTHX https://www.prnewswire.com/news-releases/biotech-innovations-paving-the-way-in-breast-cancer-fight-302113730.html

User Image IzumiSusuki Posted - 6 days ago

$GTHX I think this is when ADC data will drop. Just a feeling. They put the IA data of that phase two out at a conference. No crystal ball, but it they sign up foe this, I think it drops before and they review it at the conference in depth

User Image StephCasi97 Posted - 6 days ago

$GTHX Chart looks terrible. Heading for gap fill

User Image opgenopgen Posted - 1 week ago

$GTHX U.S. High Growth Tech and AI Stocks..... https://simplywall.st/discover/investing-ideas/215171/high-growth-tech-and-ai-stocks/us?via=bullmarketstocks

User Image IzumiSusuki Posted - 1 week ago

$GTHX I didn’t know the bombing attempt in Israel would impact Cosela stock

User Image InvestorABCD Posted - 1 week ago

$GTHX Pain.

User Image Rbk0919 Posted - 1 week ago

$GTHX

User Image jerry68 Posted - 1 week ago

$GTHX jack did a nice job . Explained the benefits of Cossella to a tee.

User Image IzumiSusuki Posted - 1 week ago

$GTHX Just two more full weeks - then some earnings

User Image G101SPM Posted - 1 week ago

$GTHX $4.59 last bid. DAC (4) $1.814 last $1.23 (1.17.23). EXIT $12.00 - Legacy Holding (LH). NEWS: Needham analyst Gil Blum reiterates G1 Therapeutics(GTHX) with a Buy and maintains $12 price target.

User Image Lskynrd1 Posted - 1 week ago

$GTHX Biden's commentary on what the Fed will do is inappropriate. Where is the independence of the Fed and monetary policy targeting prices not simply targeting political outcomes. DC is so broken not looking out for working class anymore. So much I could say but I'll leave that for Chance, he's pretty accurate

User Image IzumiSusuki Posted - 1 week ago

$GTHX anyone know when the presentation is today? I saw 8:45 ET on the post but that might be when the whole conference started. Anything new? Prob not

User Image chance111 Posted - 1 week ago

$GTHX Anybody who does not understand that inflation is a problem and will continue to be a problem as long as this administration remains in control. With the out of control spending that is even getting worse and the regulations on fossil fuel, things will only get worse. This will continue to be a drag on stocks including G1.Hopefully, it will not destroy the potential in G1 that we all see. Smart investors will begin looking at the WHOLE PICTURE.

Analyst Ratings
Needham Buy Apr 12, 24
Needham Buy Feb 28, 24
Wedbush Outperform Feb 13, 24
Needham Buy Feb 13, 24
Needham Buy Jan 24, 24
Needham Buy Dec 6, 23
Wedbush Outperform Oct 30, 23
JP Morgan Underweight Oct 6, 23
Wedbush Outperform Aug 3, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Umstead John W. V Chief Financial Offi.. Chief Financial Officer Jan 03 Sell 3.06 743 2,274 130,443 01/08/24
Malik Rajesh Chief Medical Office.. Chief Medical Officer Jan 03 Sell 3.06 3,740 11,444 169,938 01/08/24
Perry Andrew Chief Commercial Off.. Chief Commercial Officer Jan 03 Sell 3.12 2,413 7,529 87,102 01/08/24
Bailey John E. (Jack) Jr. President and CEO President and CEO Jan 03 Sell 3.12 11,686 36,460 489,594 01/08/24
Avagliano Mark Chief Business Offic.. Chief Business Officer Jan 03 Sell 3.06 4,081 12,488 117,834 01/08/24
MURDOCK TERRY L Chief Operating Offi.. Chief Operating Officer Jan 03 Sell 3.06 3,740 11,444 103,638 01/08/24
Bailey John E. (Jack) Jr. President and CEO President and CEO Jan 02 Sell 3.2746 32,983 108,006 400,580 01/02/24
Moses Jennifer K. CFO CFO Jan 03 Sell 5.49 2,368 13,000 57,820 01/05/23
MURDOCK TERRY L Chief Operating Offi.. Chief Operating Officer Jan 03 Sell 5.49 2,368 13,000 36,439 01/05/23
Perry Andrew Chief Commercial Off.. Chief Commercial Officer Jan 03 Sell 5.58 820 4,576 21,300 01/05/23
Malik Rajesh Chief Medical Office.. Chief Medical Officer Jan 03 Sell 5.49 2,368 13,000 102,739 01/05/23
Hanson James S. General Counsel General Counsel Jan 03 Sell 5.49 2,368 13,000 41,087 01/05/23
Bailey John E. (Jack) Jr. President and CEO President and CEO Jan 03 Sell 5.72 37,626 215,221 276,282 01/05/23
Velleca Mark A. Director Director Oct 18 Sell 11.7 15,000 175,500 116,000 10/20/22
Velleca Mark A. Director Director Oct 18 Option 0.39 15,000 5,850 131,000 10/20/22
Moses Jennifer K. CFO CFO Feb 01 Option 3.95 2,333 9,215 37,888 02/02/22
Malik Rajesh Chief Medical Office.. Chief Medical Officer Feb 01 Option 0.30 10,000 3,000 73,855 02/02/22
Velleca Mark A. Director Director Apr 15 Option 0.39 30,000 11,700 51,000 04/15/21
Velleca Mark A. Director Director Apr 15 Sell 24.46 30,000 733,800 41,000 04/15/21
Malik Rajesh Chief Medical Office.. Chief Medical Officer Jan 22 Option 4.17 15,000 62,550 55,200 01/22/21
Malik Rajesh Chief Medical Office.. Chief Medical Officer Jan 22 Sell 20.64 15,000 309,600 40,200 01/22/21
Velleca Mark A. Director Director Jan 21 Option 2.89 34,000 98,260 51,000 01/21/21
Velleca Mark A. Director Director Jan 21 Sell 21.01 30,000 630,300 41,000 01/21/21
RUDNICK SETH Director Director Dec 23 Sell 20.26 32,092 650,184 6,190 12/23/20
Velleca Mark A. President and CEO President and CEO Dec 17 Option 3.72 30,000 111,600 47,000 12/17/20
Velleca Mark A. President and CEO President and CEO Dec 17 Sell 19.53 30,000 585,900 37,000 12/17/20
RUDNICK SETH Director Director Dec 10 Sell 20.17 19,480 392,912 38,282 12/10/20
Bailey John E. (Jack) Jr. Director Director Nov 13 Buy 12.8 8,000 102,400 8,000 11/13/20